Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

532 results about "Natural killer cell" patented technology

Natural killer cells, or NK cells, are a type of cytotoxic lymphocyte critical to the innate immune system. The role NK cells play is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells provide rapid responses to virus-infected cells, acting at around 3 days after infection, and respond to tumor formation. Typically, immune cells detect the major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. NK cells are unique, however, as they have the ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction. They were named "natural killers" because of the initial notion that they do not require activation to kill cells that are missing "self" markers of MHC class 1. This role is especially important because harmful cells that are missing MHC I markers cannot be detected and destroyed by other immune cells, such as T lymphocyte cells.

Stealth lipid nanoparticle compositions for cell targeting

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., immune effector cells such as T cells, B cells, natural killer cells, and dendritic cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Owner:GENERATION BIO CO

CD83-binding chimeric antigen receptors

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Isolation and expansion of natural killer cells using fluorescence-activated droplet sorting

PCT designated stage expiredWO2025050133A1Flow mixersTransportation and packagingNatural Killer Cell Inhibitory ReceptorsCellular Expansion
A high-throughput microfluidics-based fluorescence activated droplet sorting (FADS) system provides activation, sorting, and feeder cell-free expansion of NK cells that are enriched for killing activity. The NK cells are activated and identified based on their ability to kill target cells, such as tumor cells, without prior sensitization. The diversity of endogenous NK cells can be overcome to allow selection of a highly effective population of cells for therapeutic use, such as in the treatment of cancer.
Owner:NORTHEASTERN UNIV (US)

Humanized immunodeficient mouse model

PendingCN120051204ACompounds screening/testingUnknown materialsImmunodeficient mouse modelHuman cell
In some aspects, the disclosure provides humanized immunodeficient mouse models that support long term transplantation and function of human T cells, natural killer cells, and bone marrow cells without the need for conditioning.
Owner:JACKSON LAB THE +1

Engineered natural killer cells with enhanced tumor killing performance

The invention relates to an engineered natural killer cell, in particular to a natural killer cell with enhanced tumor killing performance, a polynucleotide for coding CAR19 and a polynucleotide for coding IL-24 are integrated in a genome of the natural killer cell, and the engineered natural killer cell simultaneously expresses CAR19 and IL-24.
Owner:SHANGHAI PINPOINT MEDICAL TECH CO LTD

Devices and methods for modulating immune system activity in a cancer patient and treating cancer

Described herein are methods and devices for monitoring or modulating an immune system in a subject with cancer, and methods and devices for treating a cancer in a subject. The implanted device can electrically stimulate the splenic nerve of the subject, which can modulate the inflammatory system (for example, by increasing or decreasing the blood level of one or more pro-inflammatory cytokines and / or anti-inflammatory cytokines to increase or decrease inflammation in the subject) and / or activate or increase circulation of one or more immune cells (such as natural killer cells and / or cytotoxic T-cells), for the treatment of cancer. The implanted medical device includes two or more electrodes configured to electrically stimulate the splenic nerve, and may further include an ultrasonic transducer configured to receive ultrasonic waves and convert energy from the ultrasonic waves into an electrical energy that powers the device.
Owner:IOTA BIOSCIENCES INC

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and / or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
Owner:NKARTA INC

Combined medicine for preventing and / or treating prostatic cancer, application of combined medicine and pharmaceutical composition

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Compositions and methods for immune cell modulation in adoptive immunotherapies

Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naïve, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
Owner:FATE THERAPEUTICS INC

Dual-targeting chimeric antigen receptor, recombinant expression vector, anti-tumor natural killer cell and application

The invention relates to the technical field of tumor immunotherapy, in particular to a dual-targeting chimeric antigen receptor, a recombinant expression vector, an anti-tumor natural killer cell and application, and provides a PD1-DAP10-41BB-P2A-NKG2D-Ig4-CD28-41BB-CD3 zeta fusion receptor.The dual-targeting chimeric antigen receptor can target PD-L1 on the surface of a tumor cell, can also recognize NKG2DLs and can be used for preparing anti-tumor natural killer cells. The broad spectrum of the NK cells is greatly improved, and meanwhile, the immune escape of tumor cells is also reduced.
Owner:XINXIANG MEDICAL UNIV

Fusion protein comprising IL-2 protein and CD80 protein, and use thereof

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.
Owner:GI INNOVATION INC

Method of treating alzheimer's disease with expanded natural killer cells

A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Owner:NKMAX CO LTD

Vaccines comprising peripheral blood mononuclear cells loaded with natural killer t cell ligands and antigens

The present invention relates to an immunoprophylactic and therapeutic vaccine comprising a peripheral blood mononuclear cell loaded with a natural killer T cell ligand and an antigen, and more particularly, to an immunotherapeutic vaccine comprising a peripheral blood mononuclear cell loaded with alpha-galactosylceramide, a natural killer T cell ligand and a glycolipid. The compositions of the present invention are readily available because there is no need to isolate specific cells from peripheral blood mononuclear cells. Besides, the immunization of the peripheral blood mononuclear cells loaded with the natural killer T cell ligands and antigens not only induces the obvious-level activation of the natural killer cells and the natural killer T cells and the response of cytotoxic T lymphocytes, but also has a synergistic treatment effect in the aspect of treating malignant tumors. Therefore, the compound can be beneficially used as an anti-cancer immunotherapeutic agent.
Owner:HILLIDE CO LTD

Method of treating parkinson's disease with expanded natural killer cells

Provided herein is a method for treating Parkinson's disease (PD). The method can include identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating PD.
Owner:NKMAX CO LTD

Fusion protein comprising IL-2 protein and CD80 protein, and use thereof

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.
Owner:GI INNOVATION INC

Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
Owner:NOVARTIS AG +1

Gene editing target gene to enhance natural killer cell function

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are gene edited (e.g., using Crispr / Cas) to modulate, reduce, or otherwise eliminate expression of one or more endogenous genes. In several embodiments, the edited cells are engineered to express chimeric antigen receptors that target tumor antigens (e.g., CD19, ligands of the NKG2D receptor, CD70, and / or BCMA, etc.). In several embodiments, the editing enhances one or more aspects of immune cell efficacy in cellular immunotherapy, including cytotoxicity (e.g., ADCC) and / or persistence.
Owner:NKARTA INC

Il-12 activates NK cells transfected with car RNA-lnp

The present disclosure provides a method for preparing natural killer (NK) cells with increased secretion of cytokines and increased cytotoxicity. The present invention uses IL-12 during transfection to generate CAR-NK cells with increased functional activities (cytotoxicity and secretion of cytokines) against tumor cells.
Owner:PROMAB BIOTECH +1

CD19 and CD22 chimeric antigen receptors and uses thereof

The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and / or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and / or CD19, methods of making a cell comprising the same and vectors encoding the same.
Owner:NOVARTIS AG

Antibodies to TIGIT

The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
Owner:ARCUS BIOSCIENCES INC

Methods for enhancement of engineered cell therapies in cancer treatment

Methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the proinflammatory to anti-inflammatory shift observed during the course of certain cancers, co-administered with one or more types of engineered cells such as, without limitation, CAR T-cells, engineered natural killer cells, engineered stem cells or the like. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and / or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for cancers.
Owner:PURDUE RES FOUND

Fusion protein comprising il-2 protein and CD80 protein, and use thereof

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.
Owner:GI INNOVATION INC

Universal T cells and the method of use thereof

A series of recombinant DNA constructs and a method is disclosed for use in immunological therapy in general; and in disrupting T cell receptor (TCR), human leukocyte antigens (HLA) class I and NKG2D (Natural-Killer Group 2, member D) ligand expression in particular, with the effect of producing highly compatible autologous universal T cells for further genetically engineering for allogeneic administration. A Universal T (UT) construct is provided and used, comprising a TCR antibody fragment fused to a transmembrane domain (TMD) and ER retention domain of adenovirus early region 3 glycoprotein E3-19k (E3 / 19K) (TCR-E3 / 19K RD). The Universal T (UT) construct can hijack ERAD machinery to arrest TCR and HLA molecules in endoplasmic reticulum (ER) and facilitate their translocation into the cytoplasm for ubiquitination and degradation by proteasomes.
Owner:ST PHI THERAPEUTICS +1

Methods for detecting dysfunctional NK cells in leukemia patients

Provided herein are, inter alia, methods for identifying dysfunctional natural killer (NK) cells in a subject with leukemia. Provided are methods for treating leukemia, including administering to the subject an effective amount of allogeneic NK cells.
Owner:CITY OF HOPE +1

Recombinant porcine alpha and gamma interferon

PendingCN119709765AFermentationGenetic engineeringInterferon alphaT cell
The invention belongs to the technical field of veterinary medicine, and provides a co-expressed recombinant porcine alpha and gamma interferon. The I-type interferon alpha and the II-type interferon gamma not only exert the anti-virus, anti-cell division and immune regulation effects of the interferon, but also can activate T cells and natural killer cells, and fully exert the multiple activities of the interferon. The two interferons are co-expressed in insect cells, the expression protein can be folded and then processed and modified, the structure of the expression protein is closer to a natural structure, the biological activity is high, the recombinant protein is easy to purify, the production scale is easy to expand, and live viruses or potential dangerous pathogens do not need to be treated, so that the production cost is reduced; by optimizing the production process and fermentation conditions, the quality and stability of the recombinant protein can be further improved.
Owner:INST OF ANIMAL SCI & VETERINARY MEDICINE SHANDONG ACADEMY OF AGRI SCI

Fermentate with anti-inflammatory and immune modulating properties

ActiveUS12370227B1AntipyreticAnalgesicsDecreased T cell activationFermentation
A fermentation process is disclosed that produces an immunomodulatory product. The process includes combining a source of starch, a source of sugar, and a source of a trace mineral with probiotic microorganisms and fermenting aerobically and anaerobically, thereby producing an immunomodulatory product. Turmeric is added before or after fermentation. The immunomodulatory product is also disclosed. Also provided are uses of the immunomodulatory product, such as to decrease inflammation in a subject. These methods can include increasing function of natural killer cells, decreasing T cell activation, altering CD69 expression on immune cells, and / or altering cytokine expression in a subject.
Owner:ITE INVESTMENTS LLC